TrialFrontiers in immunology2026

Predictors and responses to varying durations of BTK inhibitor bridging therapy before anti-CD19 CAR-T cell therapy in patients with relapsed/refractory DLBCL.

Jia Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.